Haemonetics (NYSE:HAE) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Haemonetics (NYSE:HAE - Free Report) in a research report report published on Friday, MarketBeat reports. The firm issued an overweight rating and a $116.00 price target on the medical instruments supplier's stock.

HAE has been the subject of several other research reports. Bank of America initiated coverage on Haemonetics in a report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price target for the company. JMP Securities restated a "market outperform" rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. CL King started coverage on shares of Haemonetics in a report on Friday, September 13th. They issued a "buy" rating and a $116.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and issued a $112.00 price target on shares of Haemonetics in a research report on Tuesday. Finally, BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 target price for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $108.78.

Haemonetics Price Performance

NYSE:HAE traded up $0.52 on Friday, reaching $81.19. 519,030 shares of the company's stock traded hands, compared to its average volume of 553,307. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics has a 12 month low of $70.25 and a 12 month high of $97.97. The stock has a 50-day simple moving average of $80.65 and a 200-day simple moving average of $81.93. The firm has a market cap of $4.08 billion, a PE ratio of 33.47, a P/E/G ratio of 1.32 and a beta of 0.38.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to analysts' expectations of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics's quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the company posted $0.99 earnings per share. Equities research analysts forecast that Haemonetics will post 4.59 earnings per share for the current year.

Institutional Trading of Haemonetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Haemonetics in the second quarter valued at about $39,000. Daiwa Securities Group Inc. purchased a new position in Haemonetics in the second quarter worth $82,000. Canada Pension Plan Investment Board acquired a new position in shares of Haemonetics during the second quarter worth $83,000. Nisa Investment Advisors LLC lifted its holdings in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Haemonetics in the 2nd quarter worth $140,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.